Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: Data from PROCEED

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 4, 2014, Pages 11-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SIPULEUCEL T;

ANTIGEN PRESENTING CELL; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CASTRATION RESISTANT PROSTATE CANCER; GLEASON SCORE; HUMAN; METASTASIS; NOTE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 4 CLINICAL TRIAL (TOPIC); PREVALENCE; PRODUCT PARAMETERS;

EID: 85119459761     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
2. Clinical Trials. gov. A registry of sipuleucel-T therapy in men with advanced prostate cancer (PROCEED). http://clinicaltrials.gov/show/NCT01306890. Identifier: NCT01306890. Accessed March 25, 2014.
3. Nabhan C, Sartor O, Cooperberg MR, et al. Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED [ASCO GU abstract 64]. J Clin Oncol. 2014;32(4)(suppl).
4. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62(1):137-147.